News und Analysen
VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases
Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS
- €6.5 M non-dilutive funding including PGE in Q2 2020
- Progress report on THN102 and BBDF-101 programs
Lyon, XX June 2020 – Theranexus, a biopharmaceutical company innovating in the treatment
Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS wurde ausgewählt, auf den 80. wissenschaftlichen Sitzungen der American Diabetes Association die klinischen Phase-II-Ergebnisse zu TOTUM-63 bei Prädiabetes vorzustellen
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
VALBIOTIS Selected at the 80th Scientific Sessions of the American Diabetes Association to Present Phase II Clinical Results of TOTUM-63 in Prediabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces
Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion to attend Citi European Healthcare Conference
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
Sensorion Publishes Results of General Assembly Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
Paris and Boston, May 19th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in
NEOVACS : VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT
- End of court-ordered receivership proceedings
- Continuation of core research in lupus and allergies
- Creation of a new business investing in BioTechs and MedTechs
- New shareholder (HBR Investment
NEOVACS : DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020
Paris and Boston, May 4th, 2020 – 18.00 CET - Néovacs (Euronext Growth Paris: ALNEV) today provides an update on the ongoing insolvency proceedings.
The Paris Commercial Court will review the sole
Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company that specializes in the development of novel therapies to restore, treat and prevent
Sensorion reschedules General Assembly to May 20
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
VALBIOTIS veröffentlicht Jahresergebnisse für 2019
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
VALBIOTIS publishes its annual results for 2019
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005808/en/
Valbiotis pipeline (Photo: Business Wire)
VALBIOTI
VALBIOTIS beschleunigt seine klinische Pipeline-Entwicklung im Hinblick auf neue Indikationen: Reduzierung von kardiovaskulären und Lebersteatose-Risiken
VALBIOTIS (Paris: ALVAL) (FR0013254851 – ALVAL / PEA/-KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005751/en/
An advanced pipeline of active substances (Graphic
Im Rahmen einer globalen Partnerschaft mit Nestlé Health Science initiiert VALBIOTIS die zulassungsrelevante letzte Phase der klinischen Entwicklung von TOTUM-63
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance With Clinically Demonstrated Metabolic Health Benefits in People With Prediabetes
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
Sensorion Reports Full-year 2019 Financial Results and Business Update
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage and gene therapy biotech company which specializes in the development of novel therapies to treat, prevent and
Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for